ReviewEBioMedicine2016
Pharmacometabolomics-aided Pharmacogenomics in Autoimmune Disease.
Review in EBioMedicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Metabolomics and Pharmacometabolomics: Advancing Precision Medicine in Drug Discovery and Development.Metabolites · 2025Review
- Artificial intelligence in autoimmune diseases: a bibliometric exploration of the past two decades.Frontiers in immunology · 2025Review
- Pharmacokinetics in Pharmacometabolomics: Towards Personalized Medication.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Pharmacometabolomics Applied to Personalized Medicine in Urological Cancers.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Metabolomics in Autoimmune Diseases: Focus on Rheumatoid Arthritis, Systemic Lupus Erythematous, and Multiple Sclerosis.Metabolites · 2021Review
- Challenges in identifying large germline structural variants for clinical use by long read sequencing.Computational and structural biotechnology journal · 2020Review
- A Quantitative and Narrative Evaluation of Goodman and Gilman's Pharmacological Basis of Therapeutics.Pharmacy (Basel, Switzerland) · 2019Article
- The New Age of -omics in Urothelial Cancer - Re-wording Its Diagnosis and Treatment.EBioMedicine · 2018Review
- Novel genetic risk variants for pediatric celiac disease.Human genomics · 2016Article
- Metabolomics: Bridging the Gap between Pharmaceutical Development and Population Health.Metabolites · 2016Review
- Pharmacometabolomics Informs Viromics toward Precision Medicine.Frontiers in pharmacology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inter-individual variability has been a major hurdle to optimize disease management. Precision medicine holds promise for improving health and healthcare via tailor-made therapeutic strategies. Herein, we outline the paradigm of "pharmacometabolomics-aided pharmacogenomics" in autoimmune diseases. We envisage merging pharmacometabolomic and pharmacogenomic data (to address the interplay of genomic and environmental influences) with information technologies to facilitate data analysis as well as sense- and decision-making on the basis of synergy between artificial and human intelligence. Humans can detect patterns, which computer algorithms may fail to do so, whereas data-intensive and cognitively complex settings and processes limit human ability. We propose that better-informed, rapid and cost-effective omics studies need the implementation of holistic and multidisciplinary approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.